Cosmos Health Inc. reported record-breaking financial results for Q3 2025, with revenue at $17.11 million, a 38% increase from the previous year. Gross profit rose to $2.60 million, a 116% increase, and total operating expenses were $4.42 million. Adjusted EBITDA improved by 74%. The Company ended the quarter with $4.63 million in cash.

The Company expanded its asset base, ending the quarter with total assets of $69.49 million. Cash and cash equivalents increased to $4.63 million, and inventory rose to $5.68 million. Total liabilities were $46.36 million, and stockholders’ equity was $23.13 million. The Company maintained a disciplined approach to capital management.

Cosmos Health achieved key milestones in Q3 2025, including securing a $300 million digital financing facility, expanding operations in the U.S., and signing a contract manufacturing agreement for pharmaceutical production. The Company’s CEO, Greg Siokas, highlighted the record revenue and gross profit, as well as the strategic investments made to drive long-term growth.

Adjusted EBITDA and Adjusted Net Income (Loss) were key financial measures used by Cosmos Health to evaluate performance. Adjusted EBITDA improved by 74% in Q3 2025. The Company’s financial statements for the quarter and nine-month period showed a strong financial position, with a focus on sustainable long-term value for shareholders.

Cosmos Health Inc. is a diversified global healthcare group listed on Nasdaq. The Company owns proprietary pharmaceutical and nutraceutical brands, manufactures pharmaceuticals, and distributes a broad line of products. With a focus on innovation and expansion, Cosmos Health is committed to delivering sustainable value and driving growth in the healthcare sector.

Read more at GlobeNewswire: Cosmos Health Reports Record Q3 2025 Results with All-Time